Published in N Engl J Med on December 21, 1995
Virus dynamics and drug therapy. Proc Natl Acad Sci U S A (1997) 3.63
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1998) 2.94
Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev (2000) 2.45
Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol (2000) 2.26
Pre-existence and emergence of drug resistance in HIV-1 infection. Proc Biol Sci (1997) 2.15
Human immunodeficiency virus drug therapy and virus load. J Virol (1997) 2.05
Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2. Genitourin Med (1997) 1.94
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92
Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis (2011) 1.91
Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One (2007) 1.84
Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1996) 1.75
HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs (2012) 1.70
Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.68
Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother (1996) 1.65
Converting cancer therapies into cures: lessons from infectious diseases. Cell (2012) 1.65
Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group. CMAJ (1998) 1.59
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS (2008) 1.50
A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients. J Virol (2005) 1.32
Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology (2007) 1.28
Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother (1999) 1.25
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
Zidovudine adherence in persons with AIDS. The relation of patient beliefs about medication to self-termination of therapy. J Gen Intern Med (1997) 1.22
Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ (2002) 1.21
Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci U S A (1996) 1.20
The critical role of p38 MAP kinase in T cell HIV-1 replication. Mol Med (1997) 1.20
Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother (2004) 1.19
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Rev (2000) 1.15
Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model. J Virol (1997) 1.07
Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob Agents Chemother (2007) 1.07
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob Agents Chemother (1998) 1.02
Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. J Virol (2003) 1.02
Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother (2004) 1.00
Biochemical mechanism of HIV-1 resistance to rilpivirine. J Biol Chem (2012) 0.99
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Antimicrob Agents Chemother (2003) 0.97
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrob Agents Chemother (1998) 0.95
Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility. AIDS Res Hum Retroviruses (2008) 0.95
Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr (2011) 0.94
Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clin Diagn Lab Immunol (2003) 0.93
Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor. J Virol (1998) 0.88
Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents Chemother (2007) 0.87
The human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein zinc ejection activity of disulfide benzamides and benzisothiazolones: correlation with anti-HIV and virucidal activities. Antimicrob Agents Chemother (1997) 0.86
Quantitative analysis of a parasitic antiviral strategy. Antimicrob Agents Chemother (2004) 0.86
TT virus infection in patients with chronic hepatitis B and response of TTV to lamivudine. World J Gastroenterol (2003) 0.85
The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. Am J Cancer Res (2011) 0.85
Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-beta-L-glyceropent-2-enofuranosyl)cytosine. Antimicrob Agents Chemother (2003) 0.85
Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Antimicrob Agents Chemother (1996) 0.85
Deterioration of detectable human immunodeficiency virus serum p24 antigen in samples stored for batch testing. J Clin Microbiol (1997) 0.85
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring. Antimicrob Agents Chemother (2011) 0.84
Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea. Antimicrob Agents Chemother (1997) 0.83
The role of backward mutations on the within-host dynamics of HIV-1. J Math Biol (2012) 0.83
An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa. AIDS Res Ther (2015) 0.83
High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. J Acquir Immune Defic Syndr (2013) 0.83
Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc (2017) 0.82
Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS PharmSci (2000) 0.82
Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study. Br J Clin Pharmacol (2002) 0.82
International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother (2010) 0.82
L-ATP is recognized by some cellular and viral enzymes: does chance drive enzymic enantioselectivity? Biochem J (1999) 0.82
Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals. Antimicrob Agents Chemother (2009) 0.81
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. J Clin Microbiol (2003) 0.81
HIV-1 drug resistance and resistance testing. Infect Genet Evol (2016) 0.80
The longitudinal impact of HIV+ parents' drug use on their adolescent children. Am J Orthopsychiatry (2009) 0.79
Abacavir/lamivudine combination in the treatment of HIV: a review. Ther Clin Risk Manag (2010) 0.79
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother (2011) 0.79
Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys. Antimicrob Agents Chemother (2005) 0.79
The Clinical Implications of Reduced Viral Fitness. Curr Infect Dis Rep (2004) 0.78
Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future. J Int AIDS Soc (2006) 0.78
Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother (1997) 0.78
Harnessing pharmacogenomics to tackle resistance to the "nucleoside reverse trancripatse inhibitor" backbone of highly active antiretroviral therapy in resource limited settings. Open AIDS J (2008) 0.78
Inhibition of replication of hepatitis B virus by cytallene in vitro. Antimicrob Agents Chemother (1997) 0.77
A varying-coefficient method for analyzing longitudinal clinical trials data with nonignorable dropout. Contemp Clin Trials (2011) 0.77
Disease management--constructing optimal NRTI-based combinations: past, present, and future. MedGenMed (2006) 0.75
A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation. J Virol (2012) 0.75
Association of hematological profile of human immunodeficiency virus-positive patients with clinicoimmunologic stages of the disease. J Lab Physicians (2013) 0.75
Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (1996) 0.75
A quarter-century of antiviral therapy. N Engl J Med (1995) 0.75
Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother (2002) 0.75
Antiretroviral therapy for human immunodeficiency virus infection in 1997. West J Med (1997) 0.75
High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. Dig Dis Sci (2011) 0.75
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med (1996) 7.06
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother (1993) 4.96
A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med (1995) 4.84
HIV viral load markers in clinical practice. Nat Med (1996) 4.78
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med (2001) 3.78
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis (1998) 3.69
Clinical utility of surface EMG: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology (2000) 3.42
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Vancomycin-resistant gram-positive bacteria isolated from human sources. J Clin Microbiol (1988) 2.71
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med (1988) 2.68
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology (1999) 2.64
Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol (1999) 2.40
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med (1995) 2.26
Use of phi(glp-lac) in studies of respiratory regulation of the Escherichia coli anaerobic sn-glycerol-3-phosphate dehydrogenase genes (glpAB). J Bacteriol (1984) 2.13
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis (2000) 2.06
Methane in lake kivu: new data bearing on its origin. Science (1973) 1.92
Mount st. Helens volcano: recent and future behavior. Science (1975) 1.89
Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol (1994) 1.85
An evaluation of the use of statistical methodology in the Journal of Infectious Diseases. J Infect Dis (1984) 1.82
Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve (1991) 1.77
THE AGE OF SALT MARSH PEAT AND ITS RELATION TO RECENT CHANGES IN SEA LEVEL AT BARNSTABLE, MASSACHUSETTS. Proc Natl Acad Sci U S A (1962) 1.76
Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS (2001) 1.74
Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis (1991) 1.70
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis (1999) 1.67
Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis (2000) 1.64
A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med (1996) 1.64
Escherichia coli mutant with altered respiratory control of the frd operon. J Bacteriol (1985) 1.61
Stimulatory effect of counterflow centrifugal elutriation in large-scale separation of peripheral blood monocytes can be reversed by storing the cells at 37 degrees C. J Clin Apher (1991) 1.61
Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis (1998) 1.58
Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med (2005) 1.58
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med (1993) 1.54
The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr (1991) 1.51
Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature. Medicine (Baltimore) (1983) 1.50
Infection of the retina by human immunodeficiency virus type I. N Engl J Med (1987) 1.50
The clinical significance of bundle branch block complicating acute myocardial infarction. 1. Clinical characteristics, hospital mortality, and one-year follow-up. Circulation (1978) 1.48
Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. Clin Immunol (1999) 1.47
Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med (2001) 1.47
Strength training increases insulin action in healthy 50- to 65-yr-old men. J Appl Physiol (1985) (1994) 1.46
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis (1995) 1.46
Leptotrichia buccalis bacteremia in patients with cancer: report of four cases and review. Rev Infect Dis (1991) 1.46
A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol (1992) 1.45
Metastatic breast tumors imitating primary colonic malignancies. Isr Med Assoc J (2000) 1.45
Electrophysiologic changes in lumbar spinal cord after cervical cord injury. Neurology (1992) 1.42
Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J Infect Dis (1990) 1.41
Would I choose dentistry again? N Y State Dent J (1991) 1.40
Reliability and validity of an algorithm for fuzzy tissue segmentation of MRI. J Comput Assist Tomogr (1998) 1.40
Combined central and peripheral myelinopathy. Neurology (1987) 1.40
A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology (2000) 1.35
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis (1999) 1.30
Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother (1989) 1.30
Strength training increases resting metabolic rate and norepinephrine levels in healthy 50- to 65-yr-old men. J Appl Physiol (1985) (1994) 1.29
Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med (1997) 1.27
The clinical significance of bundle branch block complicating acute myocardial infarction. 2. Indications for temporary and permanent pacemaker insertion. Circulation (1978) 1.26
Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother (1989) 1.25
Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab (2001) 1.25
Three classes of Escherichia coli mutants selected for aerobic expression of fumarate reductase. J Bacteriol (1986) 1.25
Analysis of terminal structures of RNA from potato virus X. Nucleic Acids Res (1978) 1.24
U.S. Geological Survey Radiocarbon Dates IV. Science (1958) 1.24
Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals. Antimicrob Agents Chemother (2000) 1.20
Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother (2001) 1.20
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg (1996) 1.20
A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants. J Acquir Immune Defic Syndr (2001) 1.19
Strong and macroporous calcium phosphate cement: Effects of porosity and fiber reinforcement on mechanical properties. J Biomed Mater Res (2001) 1.17
Wear and mechanical properties of nano-silica-fused whisker composites. J Dent Res (2004) 1.17
Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother (1998) 1.16
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis (2000) 1.13
Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate (2000) 1.12
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis (1996) 1.11
Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene (1996) 1.11
Motor neuropathy due to docetaxel and paclitaxel. Neurology (1996) 1.08
Effects of antifungal agents on the function of human neutrophils in vitro. Antimicrob Agents Chemother (1990) 1.08
Bordetella bronchiseptica infection in human immunodeficiency virus-infected patients. Clin Infect Dis (1999) 1.08
Petroleum pollutants in surface and groundwater as indicated by the carbon-14 activity of dissolved organic carbon. Science (1975) 1.07
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis (1996) 1.07
Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer (2001) 1.06
A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology (1999) 1.05
Pertussis in a previously immunized child with human immunodeficiency virus infection. J Pediatr (1989) 1.05
Disseminated cutaneous and meningeal sporotrichosis in an AIDS patient. Diagn Microbiol Infect Dis (1994) 1.05
Processing and properties of strong and non-rigid calcium phosphate cement. J Dent Res (2002) 1.05
Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Arch Intern Med (1991) 1.04
Dialysance studies of varied solutes and biochemical changes during hemodialysis. Trans Am Soc Artif Intern Organs (1964) 1.03
Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev Infect Dis (1990) 1.03
Primary hyperparathyroidism in children. J Pediatr Surg (1986) 1.02
Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol (2000) 1.02
Prospective study of the features, indications, and surgical treatment in 513 consecutive patients affected by Crohn's disease. Surgery (1997) 1.00
Partial splenectomy in Gaucher's disease. J Pediatr Surg (1986) 0.99